Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Box 85500, 3508 GA, Utrecht, The Netherlands.
Department of Rheumatology, Meander Medical Center, Amersfoort, The Netherlands.
Clin Rheumatol. 2018 Jul;37(7):1879-1884. doi: 10.1007/s10067-018-3980-y. Epub 2018 Jan 27.
To establish whether dual-energy CT (DECT) is a diagnostic tool, i.e., associated with initiation or discontinuation of a urate lowering drug (ULD). Secondly, to determine whether DECT results (gout deposition y/n) can be predicted by clinical and laboratory variables. Digital medical records of 147 consecutive patients with clinical suspicion of gout were analyzed retrospectively. Clinical data including medication before and after DECT, lab results, and results from diagnostic joint aspiration and DECT were collected. The relationship between DECT results and clinical and laboratory results was evaluated by univariate regression analyses; predictors showing a p < 0.10 were entered in a multivariate logistic regression model with the DECT result as outcome variable. A backward stepwise technique was applied. After the DECT, 104 of these patients had a clinical diagnosis of gout based on the clinical judgment of the rheumatologist, and in 84 of these patients, the diagnosis was confirmed by demonstration of monosodium urate (MSU) crystals in synovial fluid (SF) or by positive DECT. After DECT, the current ULD was modified in 33 (22.4%) of patients; in 29 of them, ULD was started and in 1 it was intensified. Following DECT, the current ULD was stopped in three patients. In the multivariable regression model, cardiovascular disease (OR 3.07, 95% CI 1.26-7.47), disease duration (OR 1.008, 95% CI 1.001-1.016), frequency of attack (OR 1.23, 95% CI 1.07-1.42), and creatinine clearance (OR 2.03, 95% CI 0.91-1.00) were independently associated with positive DECT results. We found that the DECT result increases the confidence of the prescribers in their decision to initiation or discontinuation of urate lowering therapy regimen in of mono- or oligoarthritis. It may be a useful imaging tool for patients who cannot undergo joint aspiration because of contraindications or with difficult to aspirate joints, or those who refuse joint aspiration. We also suggest the use of DECT in cases where a definitive diagnosis cannot be made from signs, symptoms, and MSU analysis alone.
为了确定双能 CT(DECT)是否是一种诊断工具,即是否与启动或停止尿酸降低药物(ULD)有关。其次,确定 DECT 结果(痛风沉积 y/n)是否可以通过临床和实验室变量来预测。对 147 例连续疑似痛风患者的临床资料进行回顾性分析。收集了 DECT 前后的临床用药、实验室结果、关节抽吸和 DECT 的结果。通过单变量回归分析评估 DECT 结果与临床和实验室结果之间的关系;将预测值 p<0.10 的变量纳入以 DECT 结果为因变量的多变量逻辑回归模型。采用向后逐步技术。在 DECT 后,根据风湿病医生的临床判断,其中 104 例患者有临床痛风诊断,在这 84 例患者中,滑液(SF)中证实有单钠尿酸盐(MSU)晶体或 DECT 阳性,诊断为痛风。在 DECT 后,33 例(22.4%)患者当前的 ULD 发生了改变;其中 29 例开始了 ULD,1 例加强了 ULD。在 DECT 后,有 3 例患者停止了当前的 ULD。在多变量回归模型中,心血管疾病(OR 3.07,95%CI 1.26-7.47)、疾病持续时间(OR 1.008,95%CI 1.001-1.016)、发作频率(OR 1.23,95%CI 1.07-1.42)和肌酐清除率(OR 2.03,95%CI 0.91-1.00)与 DECT 阳性结果独立相关。我们发现,DECT 结果增加了医生对启动或停止单关节炎或寡关节炎尿酸降低治疗方案的决策信心。对于因禁忌证或难以抽吸关节而无法进行关节抽吸,或拒绝关节抽吸的患者,它可能是一种有用的成像工具。我们还建议在仅凭体征、症状和 MSU 分析无法做出明确诊断的情况下使用 DECT。